Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

SystImmune and BMS Enter Exclusive Global Collaboration Agreement to Develop BL-B01D1

Dec 6, 2023

SystImmune and Bristol Myers Squibb announced that they have entered into an exclusive  global license and collaboration agreement for SystImmune’s BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate.  Under the agreement the companies will jointly develop and commercialise BL-B01D1 in the US.  SystImmune through its affiliates will be responsible for development, manufacturing and commercialisation in China and will be responsible for manufacturing certain drug supplies for use outside of China.  BMS will be responsible for development and commercialisation of BL-B01D1 in the rest of the world.

BL-B01D1 is currently being evaluated in a global phase I study (BL-B01D1-LUNG101) for safety and efficacy in individuals with metastatic or unresectable non-small cell lung cancer (NSCLC).